Sharpe ratio is not yet available for CAI. This metric requires at least 12 months of historical daily returns to calculate. Check back once this data is available.
How it compares to other similar stocks
The table compares Caris Life Sciences, Inc's Sharpe Ratio with other stocks in the Biotechnology industry across multiple time periods, showing how CAI's risk-adjusted performance compares to industry peers.
Data shows 1-, 5-, and 10-year periods, plus each stock's all-time average, as of Jun 4, 2026.
| Symbol | Name | 1Y Sharpe Ratio | 5Y Sharpe Ratio | 10Y Sharpe Ratio | All Time Sharpe Ratio |
|---|---|---|---|---|---|
| RVMDW | Revolution Medicines Inc. Warrant | 13.27 | |||
| SLGL | Sol-Gel Technologies Ltd. | 8.83 | |||
| ERAS | Erasca, Inc. | 7.93 | |||
| CLYM | Climb Bio Inc | 7.18 | |||
| NBTX | Nanobiotix S.A. | 6.97 | |||
| DRTSW | Alpha Tau Medical Ltd. Warrant | 6.84 | |||
| RLMD | Relmada Therapeutics, Inc. | 6.63 | |||
| TNGX | Tango Therapeutics, Inc. | 6.52 | |||
| OVID | Ovid Therapeutics Inc. | 6.24 | |||
| DNTH | Dianthus Therapeutics Inc. | 5.83 | |||
| CAI | Caris Life Sciences, Inc | — |
Loading charts...
How does CAI fit in your portfolio?
Add your other holdings to see your portfolio's Sharpe Ratio and find out.
Analyze Your Portfolio